Clinical outcomes in 21-hydroxylase deficiency

  title={Clinical outcomes in 21-hydroxylase deficiency},
  author={Anna Nordenstr{\"o}m and Svetlana Lajic and Henrik Falhammar},
  journal={Current Opinion in Endocrinology \& Diabetes and Obesity},
  pages={318 - 324}
Purpose of review The introduction of synthetic glucocorticoids 70 years ago made survival possible in classic 21-hydroxylase deficiency (21OHD). The currently used glucocorticoid therapy may lead to unphysiological dosing with negative consequencies on health in addition to the problems that may arise due to androgen over-exposure. Recent findings Fertility in females with 21OHD seemed to be impaired, especially in the salt-wasting (SW) phenotype but when pregnancies did occur there was a… 
Review Article Long-Term Outcomes of Congenital Adrenal Hyperplasia
The different long-term outcomes of CAH are discussed, including elevated steroid precursor and adrenocorticotropic hormone levels, living with a congenital condition as well as the proximity of the cytochrome P450 family 21 subfamily A member 2 ( CYP21A2 ) gene to other genes.
Adrenal myelolipomas.


Clinical outcomes in the management of congenital adrenal hyperplasia
The introduction of neonatal CAH screening may enhance long-term results and monitoring of different risk factors and negative consequences should be done regularly in an attempt to improve clinical outcomes further.
Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?
Increased frequency of some cardiovascular surrogate markers in patients, most cohorts comprised young adults, and it is not known if patients will present high frequency of cardiovascular disease in the future.
Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study.
CAH was associated with excess cardiovascular and metabolic morbidity but the mechanism is not certain as the glucocorticoids were not assessed and Hypothyroidism and obesity may be an effect of close observation.
Biochemical and genetic diagnosis of 21-hydroxylase deficiency
Diagnosing classic CAH is life-saving, but diagnosing NCCAH is also important to prevent unnecessary suffering, because unnecessary suffering due to hyperandrogenism, especially in females, can be avoided by a correct diagnosis.
MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency.
A CYP21A2 mutation analysis is advocated to verify the diagnosis, for genetic counselling and for better prognostic and treatment guidance, and it is important to acknowledge that glucocorticoid treatment will lead to secondary cortisol insufficiency and the need for stress dosing.
Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis
Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors and long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals withCAH.
Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis
There do not appear to be significant differences between hydrocortisone and prednisolone therapy, and the choice of agent should be based on individual patient factors.
Increased liver enzymes in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Compared with controls, women with CAH have higher LFT, in particular patients > or =30 years and those with severe forms, probably reflecting a higher lifetime glucocorticoid exposure.
Androgen excess is due to elevated 11-oxygenated androgens in treated children with congenital adrenal hyperplasia